BioSpace News Archive

Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the “Company” or “Inspira Technologies”), a company aiming to revolutionize acute respiratory care by empowering breathing without lungs, is proud to announce the unveiling of its INSPIRA ART line at the Extracorporeal Life Support Organization (ELSO) Conference in Seattle, WA.

Jaguar Health, Inc. announced that company management will present at the LD Micro Main Event investor conference on October 3, 2023, and at the Global Capital Network Investor Conference on October 5, 2023.

Fractyl Health, a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes (T2D) and obesity, announced today its upcoming abstract presentations at the European Association for the Study of Diabetes (EASD) 2023 Scientific Congress.

Hemogenyx Pharmaceuticals plc, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, announces its unaudited interim results for the six-month period ended 30 June 2023.

Signati Medical™ is pleased to announce the issue of US patent 11,723,680 covering critical features of the bipolar handpiece used in Signati’s Sealed Vasectomy Procedure (SVP)™.

Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today announced an oral and poster presentation at the upcoming International Annual Congress of the World Muscle Society taking place October 3-7, 2023 in Charleston, South Carolina.

PercAssist, Inc., a medical device company developing innovative technology for a minimally invasive, extravascular platform to provide hemodynamic support for chronic heart failure patients, today announced the successful completion of its first patient in the EUREKA First-in-Human clinical study.

Fabre-Kramer Pharmaceuticals Inc. (Fabre-Kramer) is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved Exxua™ (gepirone hydrochloride extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Kineta, Inc., a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced its participation in the following upcoming investor conferences in October 2023.

Madrigal Pharmaceuticals, Inc. announced the pricing of its underwritten public offering of 1,248,098 shares of its common stock at a public offering price of $151.69 per share, and, to certain investors, pre-funded warrants to purchase 2,048,098 shares of common stock at a price of $151.6899 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant.